Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Aarey Drugs And Pharmaceuticals Ltd

    Aarey Drugs & Pharmaceuticals Ltd. (ADPL) was originally incorporated as a private limited company in the name of M/s. Niharika Textile and Chemicals Limited, on May 15, 1990. T

  • No Image
    Aarti Drugs Ltd

    Aarti Drugs Ltd is a part of the USD 500 million Aarti Group of Industries, Aarti Drugs Ltd (ADL) was established way back in in 1984. Since its inception, the company has estab

  • No Image
    Abbott India Ltd

    Abbott India Limited is one of India's fastest growing pharmaceutical companies. Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abb

  • No Image
    Abiba Pharmacia Private Limited

    Abiba Pharmacia Private Limited specializes in offering pharmaceutical products. Their products include pharmaceutical tablets, pharmaceutical capsules and pharmaceutical syrup.